Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply

1NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK 2Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK 3Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Nottingham, UK Email: rebecca.harris@nottingham.ac.uk

[1]  J. West,et al.  Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? , 2020, Alimentary pharmacology & therapeutics.

[2]  Suying Li,et al.  Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data , 2020, Alimentary pharmacology & therapeutics.

[3]  T. Card,et al.  Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. , 2019, The American journal of gastroenterology.

[4]  Hongliang Li,et al.  Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.

[5]  G. Pera,et al.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population‐Based Study , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  T. Card,et al.  Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross‐sectional study using transient elastography , 2018, Alimentary pharmacology & therapeutics.

[7]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[8]  M. Ziol,et al.  Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[9]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[10]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[11]  A. Hofman,et al.  Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study , 2016, Hepatology.

[12]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[13]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[14]  Robert S. Brown,et al.  Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease. , 2016, Gastroenterology & hepatology.